Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24416188 | 0.97 | MAPT (0.35) | MAPTHPGDMEN1KMT2ABRCA1 | |
| SCHEMBL24415999 | 0.96 | MEN1 (0.38) | MAPTHPGDMEN1KMT2ABRCA1 | |
| SCHEMBL24416184 | 0.92 | MEN1 (0.42) | MAPTHPGDMEN1KMT2ABRCA1 | |
| SCHEMBL24415194 | 0.89 | MAPT (0.35) | MAPTHPGDMEN1KMT2ABRCA1 | |
| SCHEMBL24415208 | 0.86 | MAPT (0.33) | MAPTHPGDMEN1KMT2ABRCA1 | |
| SCHEMBL24415492 | 0.86 | MEN1 (0.31) | MAPTHPGDMEN1KMT2ABRCA1 | |
| SCHEMBL24421843 | 0.86 | MAPT (0.36) | MAPTHPGDMEN1KMT2ABRCA1 | |
| SCHEMBL24416581 | 0.85 | MAOA (0.35) | MAPTHPGDMEN1KMT2ABRCA1 | |
| SCHEMBL24415446 | 0.83 | MAPT (0.35) | MAPTHPGDMEN1KMT2ABRCA1 | |
| SCHEMBL23229656 | 0.82 | MEN1 (0.44) | MAPTHPGDMEN1KMT2ABRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144769-A1 | COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220144759-A1 | COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144769-A1 | COMPOUND | CBR3, SFXN3, CBR1 | MAPT 4568/4885HPGD 2255/4885MEN1 1793/4885 |
| US-20220144759-A1 | COMPOUND | SFXN3, SFXN1, CBR3 | MAPT 4522/4885HPGD 1584/4885MEN1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.